Key facts
- Enterome’s last known valuation is $217.0M (Jul 2022).
- It has raised $292.3M; the latest was Later Stage VC ($19.0M) in Jun 2025.
- Notable investors include Omnes Capital, Bristol-Myers Squibb, Primo Capital (Milano), Takeda Ventures, Nestlé Health Science — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Enterome
- ·The full record, as it builds
Funding rounds
No funding rounds for Enterome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enterome
Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types. The company's approach generates a powerful, long-lasting immune response from the patient's own effector memory T-cells, overcoming the immune tolerance to self-antigens, integrated with a research and development platfo, with therm potential to deliver multiple candidates with a rapid progression, overcoming the immune tolerance to self-antigens, enabling healthcare companies to begin treatment more quickly and resulting in a likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2008
- Employees
- 78
- Website
- enterome.com/
- Ownership
- Privately Held (backing)
Enterome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enterome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enterome in its N-PORT filings yet. We sweep new filings monthly.